MedTech Dive July 3, 2024
Alcon will gain access to a laser treatment for glaucoma that it plans to sell in the U.S. by the end of the year.
Dive Brief:
- Alcon completed its takeover of glaucoma device developer Belkin Vision, the company said Monday.
- The deal, which is worth $81 million upfront and up to $385 million in milestone payments, gives Alcon control of laser technology for treating open angle glaucoma and ocular hypertension.
- Alcon already sells implants and drops for treating eye conditions. The company, which plans to launch the Belkin device in the U.S. this year, said treatment is shifting to first-line laser therapy.
Dive Insight:
Selective laser trabeculoplasty (SLT) has emerged as an alternative to eye drops to improve...
Today's Sponsors
Today's Sponsor